Author:
Vuletić Lucija,Khan M. Zahirul I.,Špoljarić Drago,Radić Maja,Cetina-Čižmek Biserka,Filipović-Grčić Jelena
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference37 articles.
1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Waiver of In vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000.
2. European Medicines Agency. Guideline on the investigation of bioequivalence. 2010. (EMA/CPMP/EWP/QPW/1401/98 Rev. 1 Corr.*).
3. Li S, He H, Parthiban LJ, Yin H, Serajuddin AT. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci. 2005;94(7):1396–417.
4. Bredael GM, Bowers N, Boulineau F, Hahn D. In vitro–in vivo correlation strategy applied to an immediate-release solid oral dosage form with a Biopharmaceutical Classification System IV compound case study. J Pharm Sci. 2014;103(7):2125–30.
5. Honorio Tda S, Pinto EC, Rocha HV, Esteves VS, dos Santos TC, Castro HC, et al. In vitro–in vivo correlation of efavirenz tablets using GastroPlus®. AAPS PharmSciTech. 2013;14(3):1244–54.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献